This was achieved by testing the response of tumor cells, which were isolated from an MPE sample of a treatment‐naïve EGFR‐driven NSCLC patient, to targeted treatments and followed by correlation with genetic alterations and clinical outcomes. This evidence concerns the gene EGFR and neoplasm.